Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Healius Limited ( (AU:HLS) ) has shared an update.
Healius Limited has announced the appointment of Andrew Thomson as the new Chief Financial Officer, succeeding Steve Humphries who is retiring. Thomson brings extensive experience from his previous roles in multinational businesses, which is expected to aid Healius in executing its T27 strategic plan. Additionally, Eric Swayn has been appointed as the National Laboratory Operations Manager, bringing over 25 years of experience in the Australian pathology industry. These appointments are anticipated to strengthen Healius’s operational leadership and support its strategic objectives.
The most recent analyst rating on (AU:HLS) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.
More about Healius Limited
Healius Limited is a leading healthcare company in Australia, dedicated to providing quality, affordable, and accessible healthcare services. With over 8,000 employees, Healius offers specialty pathology services across the country, serving both consumers and referring practitioners.
Average Trading Volume: 4,754,304
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$584.5M
For detailed information about HLS stock, go to TipRanks’ Stock Analysis page.